Statements 

This section contains statements that have been released by AABB, its task forces or the entire blood community on issues relating to transfusion medicine and cellular therapies. Click on a link below to read current statements. For access to past statements, check our archive.

AABB Statement on XMRV – 9/22/11
Joint Statement Before BPAC on Maintaining a Safe and Adequate Supply of Donated Blood During a Severe Emergency – 8/3/11
Joint Statement Before BPAC on T. cruzi Incidence Study of Blood Donors and Its Implications for Selective Donor Testing – 8/2/11
Statement Before ACBSA on Patient Blood Management – 6/8/11
Statement Before BPAC on the Donor Written Statement of Understanding – 4/29/11
Statement Before BPAC by Interorganizational Plasma Task Force on Plasma for Further Manufacture – 4/28/11
AABB Statement on XMRV – 2/10/11
Statement Before BPAC on Murine Leukemia Virus (MLV) Related Retroviruses and Blood Safety - 12/14/10
Joint Statement Before BPAC on Risk of Dengue Virus Infection in Blood Donors - 12/14/10
Statement Before BPAC on Hemoglobin/Hematocrit Acceptance Standards and Interdonation Intervals – 7/27/10
Statement Before BPAC on Babesia Infection Risk by Blood Transfusion and Potential Strategies for Donor Testing – 7/26/10
Joint Statement Before ACBSA on Donor Deferral for Men Who Have Had Sex with Another Man (MSM) – 6/15/10
Statement Before BPAC on Blood Pressure and Pulse as Blood Donor Eligibility Criteria – 11/17/09 (PDF)
Statement Before BPAC on Blood Donor Deferral for Malaria Risk Associated With Travel to Mexico – 11/16/09 (PDF)
Statement Before ACBSA on Decision Making Process for Transfusion and Transplantation Safety Policies – 5/1/09
Statement Before ACBSA on U.S. Biovigilance: Efforts to Bridge a Critical Donor and Patient Safety Gap – 4/30/09
Joint Statement Before BPAC on HBV NAT Using Triplex Assay Systems – 4/1/09
Joint Statement Before BPAC on Potential Testing Strategies for T. cruzi Infection in Blood Donors – 4/1/09
Presentation Before BPAC by the AABB Interorganizational Plasma Task Force – 4/2/09 (PDF)